https://biotechmorning.com/news/compass-therapeutics-trial-crossover-problem Biotech Morning en 2026-04-28T14:13:28.669Z The Trial That Worked Too Well for Its Own Good https://biotechmorning.com/news/oruka-psoriasis-data-vs-skyrizi Biotech Morning en 2026-04-28T14:12:38.952Z The Tiny Biotech That Just Embarrassed a Billion-Dollar Drug https://biotechmorning.com/news/sun-pharma-organon-acquisition-12-billion Biotech Morning en 2026-04-28T14:11:51.311Z India's Generics King Just Bet $12 Billion It Can Play in the Big Leagues https://biotechmorning.com/news/survodutide-obesity-drug-wasnt-supposed-to-work Biotech Morning en 2026-04-28T14:11:08.851Z The Obesity Drug That Wasn't Supposed to Work https://biotechmorning.com/news/coultreon-biopharma-125m-galapagos-rescued-assets Biotech Morning en 2026-04-28T14:10:23.576Z Biotech's Hottest New Strategy: Raiding Big Pharma's Junk Drawer https://biotechmorning.com/news/astellas-gene-therapy-plan-b Biotech Morning en 2026-04-28T14:09:40.279Z Astellas Spent $3 Billion on a Gene Therapy. Now It's Trying Plan B. https://biotechmorning.com/news/two-biotechs-ipo-same-day-biotech-window Biotech Morning en 2026-04-28T14:09:05.056Z Two Biotechs Just Rang the IPO Bell on the Same Day https://biotechmorning.com/news/janux-kills-solid-tumor-t-cell-engager Biotech Morning en 2026-04-28T14:08:21.642Z Janux Just Killed Its Biggest Solid Tumor Bet. The Reason Should Worry Everyone. https://biotechmorning.com/news/novartis-in-vivo-car-t-evaluation Biotech Morning en 2026-04-28T14:07:35.789Z The Company That Invented CAR-T Is Watching From the Sidelines https://biotechmorning.com/news/lilly-profluent-ai-gene-editing-deal Biotech Morning en 2026-04-28T14:06:52.641Z Eli Lilly Just Paid $2.25 Billion for a Gene Editor That Doesn't Exist in Nature https://biotechmorning.com/news/intellia-first-in-vivo-crispr-fda-filing Biotech Morning en 2026-04-27T14:14:15.183Z One Shot to Rewrite Your DNA: The Race for the First In Vivo CRISPR Approval https://biotechmorning.com/news/lilly-ajax-therapeutics-jak-inhibitor-deal Biotech Morning en 2026-04-27T14:13:27.213Z Lilly Just Dropped $2.3 Billion on a Drug With Zero Human Data https://biotechmorning.com/news/oricell-110m-car-t-solid-tumors Biotech Morning en 2026-04-27T14:12:44.344Z The $110M Bet That CAR-T Can Finally Beat Solid Tumors https://biotechmorning.com/news/gilead-tubulis-5-billion-adc-acquisition Biotech Morning en 2026-04-27T14:12:02.395Z Gilead Just Dropped $5 Billion on a Munich Startup You've Never Heard Of https://biotechmorning.com/news/neurocrine-soleno-prader-willi-acquisition-2 Biotech Morning en 2026-04-27T14:11:19.448Z Neurocrine Just Bet $2.9 Billion on a Disease Most People Have Never Heard Of https://biotechmorning.com/news/ucb-neurona-cell-therapy-epilepsy-deal Biotech Morning en 2026-04-27T14:10:39.022Z UCB Just Bet $1.15 Billion That Brain Cells Can Cure Seizures https://biotechmorning.com/news/kidney-drug-filspari-fsgs-fda-approval Biotech Morning en 2026-04-27T14:09:54.445Z The Kidney Drug That Wasn't Supposed to Get Approved https://biotechmorning.com/news/lilly-foundayo-slow-launch-wall-street-panic Biotech Morning en 2026-04-27T14:09:14.532Z Lilly's Obesity Pill Got 1,390 Prescriptions in a Week. Wall Street Panicked. https://biotechmorning.com/news/uk-biotech-cash-no-ipos Biotech Morning en 2026-04-27T14:08:25.683Z UK Biotech Has Plenty of Cash. So Why Won't Anyone Go Public? https://biotechmorning.com/news/akt-pathway-108m-bet-terremoto Biotech Morning en 2026-04-27T14:07:45.418Z The Cancer Pathway Everyone Gave Up On Just Got a $108M Bet